Scarica l'app Stockscreener
23.09
5.24%
1.15
Dopo l'orario di chiusura:
23.11
0.02
+0.09%
Precedente Chiudi:
$21.94
Aprire:
$23.055
Volume 24 ore:
76,473
Relative Volume:
0.35
Capitalizzazione di mercato:
$329.31M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+2.44%
1M Prestazione:
+34.09%
6M Prestazione:
+48.20%
1 anno Prestazione:
-46.34%
Intervallo 1D:
$22.79
$23.48
Intervallo di 1 settimana:
$20.80
$23.50
Portata 52W:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
23.09 | 312.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Craig Hallum | Buy |
| 2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Is Neurogene Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional
What drives Neurogene Inc. stock priceMarket-crushing profits - Autocar Professional
Neurogene Inc. Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What makes Neurogene Inc. stock price move sharplyReal Time Stock Signal - Newser
What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com
how neurogene inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
How Neurogene Inc. stock performs during market volatilityHigh Return Conservative Stocks - Newser
Why Neurogene Inc. stock attracts strong analyst attentionFree Investment Community - Newser
Neurogene announces inducement grants - Medical Buyer
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Neurogene jumps as FDA approves rare gene therapy trial design - TradingView
Stifel reiterates Buy rating on Neurogene stock, backs pivotal trial design - Investing.com
FDA approves Neurogene’s Rett syndrome gene therapy registrational trial design - Investing.com
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
Neurogene Inc.(NasdaqGM: NGNE) dropped from Russell 3000E Growth Index - MarketScreener
Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance
Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World
Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus
Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria
BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World
Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus
Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):